PFAS exposure may cause early menopause in women

Per- and polyfluoroalkyl substance (PFAS) exposure may cause menopause to occur two years earlier in women, according to a new study.

from Women's Health News -- ScienceDaily https://ift.tt/3duJvqe

PFAS exposure may cause early menopause in women

Per- and polyfluoroalkyl substance (PFAS) exposure may cause menopause to occur two years earlier in women, according to a new study.

from Women's Health News -- ScienceDaily https://ift.tt/3duJvqe

Association between outdoor light at night and breast cancer risk among postmenopausal women

Outdoor light at night was linked to a higher risk of breast cancer in a recent study.

from Women's Health News -- ScienceDaily https://ift.tt/371SCwf

Association between outdoor light at night and breast cancer risk among postmenopausal women

Outdoor light at night was linked to a higher risk of breast cancer in a recent study.

from Breast Cancer News -- ScienceDaily https://ift.tt/371SCwf

Association between outdoor light at night and breast cancer risk among postmenopausal women

Outdoor light at night was linked to a higher risk of breast cancer in a recent study.

from Women's Health News -- ScienceDaily https://ift.tt/371SCwf

A satisfying romantic relationship may improve breast cancer survivors' health

Breast cancer survivors in romantic relationships who feel happy and satisfied with their partners may be at lower risk for a host of health problems, new research suggests.

from Breast Cancer News -- ScienceDaily https://ift.tt/2XvFf4o

Vitamin D determines severity in COVID-19 so government advice needs to change, experts urge

Researchers are urging the Irish government to immediately change recommendations on vitamin D supplements given recent changes by Welsh, English and Scottish governments.

from Women's Health News -- ScienceDaily https://ift.tt/2Z09gKL

Killing 'sleeper cells' may enhance breast cancer therapy

The anti-cancer medicine venetoclax could improve the current therapy for estrogen receptor-positive (ER+) breast cancer, according to preclinical studies. The promising preclinical results for this 'triple therapy' have underpinned a phase 1 clinical trial in Melbourne, Australia, that is combining venetoclax with hormone therapy and CDK4/6 inhibitors in patients with ER+ breast cancer.

from Women's Health News -- ScienceDaily https://ift.tt/2YJeieg

Killing 'sleeper cells' may enhance breast cancer therapy

The anti-cancer medicine venetoclax could improve the current therapy for estrogen receptor-positive (ER+) breast cancer, according to preclinical studies. The promising preclinical results for this 'triple therapy' have underpinned a phase 1 clinical trial in Melbourne, Australia, that is combining venetoclax with hormone therapy and CDK4/6 inhibitors in patients with ER+ breast cancer.

from Women's Health News -- ScienceDaily https://ift.tt/2YJeieg

Killing 'sleeper cells' may enhance breast cancer therapy

The anti-cancer medicine venetoclax could improve the current therapy for estrogen receptor-positive (ER+) breast cancer, according to preclinical studies. The promising preclinical results for this 'triple therapy' have underpinned a phase 1 clinical trial in Melbourne, Australia, that is combining venetoclax with hormone therapy and CDK4/6 inhibitors in patients with ER+ breast cancer.

from Breast Cancer News -- ScienceDaily https://ift.tt/2YJeieg